Marketing of Diagnostics and deCODEme(TM), Recent Progress in Drug Development to be Highlighted at deCODE... (F(TM) foratrial fibrillation and stroke;...)

Marketing of Diagnostics and deCODEme(TM), Recent Progress in Drug Development to be Highlighted at deCODE R&D Event

Date:6/30/2008

F(TM) for atrial fibrillation and stroke; deCODE MI(TM) for heart attack; deCODE ProCa(TM) for prostate cancer; and deCODE Glaucoma(TM) for a major type of glaucoma. deCODE is delivering on the promise of the new genetics(SM). Visit us on the web at http://www.decode.com; on our diagnostics website at http://www.decodediagnostics.com; and, for our pioneering personal genome analysis service, at http://www.decodeme.com.

Any statements contained in this presentation that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results, and the timing of events, to differ materially from those described in the forward-looking statements. These risks and uncertainties include, among others, those relating to our ability to obtain financing and to form collaborative relationships, uncertainty regarding potential future deterioration in the market for auction rate securities which could result in additional permanent impairment charges, our ability to develop and market diagnostic products, the level of third party reimbursement for our products, risks related to preclinical and clinical development of pharmaceutical products, including the identification of compounds and the completion of clinical trials, the effect of government regulation and the regulatory approval processes, market acceptance, our ability to obtain and protect intellectual property rights for our products, dependence on collaborative relationships, the effect of competitive products, industry trends and other risks identified in deCODE's filings with the Securities and Exchange Commission, including, without limitation, the risk fact
'/>"/>

SOURCE deCODE genetics
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3
Related medicine technology :

1. AMT Prepares for Submission of Marketing Authorization Dossier for AMT-011 (Glybera(R))
2. European Regulatory Agency Accepts Cell Therapeutics, Inc.s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review
3. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
4. Infant Formula Manufacturers Again under Ethical Cloud: Marketing Gimmick Linked to Serious Illnesses
5. Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)
6. ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study
7. ADVENTRX Announces Completion of Patient Enrollment in ANX-530 Marketing-Enabling Clinical Study
8. FDA Advisory Committees Recommend Continued U.S. Marketing Authorization for Trasylol(R)
9. Rosetta Genomics and Rabin Medical Center Announce a Collaboration Focused on MicroRNA-Based Diagnostics
10. Pressure BioSciences, Inc. Announces $850,000 NIH SBIR Phase II Award for the Development of a New PCT-dependent System for Improved Biomarker Discovery, Diagnostics, and Drug Discovery
11. Ion Mobility Diagnostic Test from Quest Diagnostics is First to Provide Direct Physical Measurement of Lipoprotein Particles, Cardiovascular Disease Indicators, Study Finds

Post Your Comments:

(Date:5/20/2013)... -- Uroplasty, Inc. (Nasdaq: UPI ) announced today ... fourth quarter and full year ended March 31, 2013 ... The Company will host a conference call and webcast ... at 4:30 p.m. Eastern Time (3:30 p.m. Central Time). ... dial 888-549-7750, no passcode is necessary. To access the ...

(Date:5/20/2013)... , May 20, 2013 /PRNewswire-iReach/ -- It is no ... one third being overweight or obese gyms and supplement companies ... time the condition is primarily related to dietary issues and ... be the result of a glandular problem or even a ... One common vitamin deficiency is a lack of vitamin ...

(Date:5/20/2013)... 20, 2013 National Community Pharmacists Association ... RPh, MBA issued the following statement today regarding a ... Part D "preferred pharmacy" drug plans , which ... plan,s lowest advertised co-payments: (Logo: http://photos.prnewswire.com/prnh/20100106/DC33253LOGO ... and MedPAC , 16 U.S. Senators ...

Breaking Medicine Technology:Uroplasty To Announce Fiscal Fourth Quarter And Full Year 2013 Financial Results On May 30, 2013 2 USB12Shots.com Discusses the Possibility of B12 Shots for Weight Loss 2 Poll: Over One Million Seniors Have Problems with Medicare 'Preferred Pharmacy' Drug Plans 2 Poll: Over One Million Seniors Have Problems with Medicare 'Preferred Pharmacy' Drug Plans 3 Poll: Over One Million Seniors Have Problems with Medicare 'Preferred Pharmacy' Drug Plans 4

[0] Uroplasty To Announce Fiscal Fourth Quarter And Full Year 2013 Financial Results On May 30, 2013 [0] USB12Shots.com Discusses the Possibility of B12 Shots for Weight Loss [0] Poll: Over One Million Seniors Have Problems with Medicare 'Preferred Pharmacy' Drug Plans

... TALLAHASSEE, Fla., Aug. 16, 2011 The National ... C.A.R.E.S. (Collaborating and Acting Responsibly to Ensure Safety) ... addressing a serious public health issue in Florida – ... today that makes August 27 a statewide Drug Take ...

... 16, 2011 /PRNewswire-Asia-FirstCall/ -- Concord Medical Services Holdings Limited ("Concord ... operator of the largest network of radiotherapy and diagnostic imaging ... earnings per ADS for its unaudited consolidated financial results for ... second quarter ended June 30, 2010. Second ...

NADDI and the C.A.R.E.S. Alliance Join Attorney General Bondi in Fight Against Prescription Drug Abuse Concord Medical Announces Higher Revenues, Net income, and Earnings per ADS for the Second Quarter 2011

(Date:5/20/2013)... York, NY (PRWEB) May 20, 2013 ... protecting the rights of victims injured by defective drugs, ... Dakota man who alleges that use of the diabetes ... The suit was filed on April 30, 2013, in ... Louisiana (Case No. 6:13-cv-0888), where it is one of ...

(Date:5/20/2013)... May 20, 2013 According to a May ... at Indoor Tanning Salons,” tanning salons in the ... Food and Drug Administration wants to see cancer warnings on ... minimum age floor of eighteen for the use of indoor ... about melanoma, which has become increasingly common over the last ...

(Date:5/20/2013)... 2013 The Environmental Design ... dozens of continuing education credit opportunities for design ... of Architects Continuing Education System (AIA/CES), the Landscape ... Interior Design Continuing Education Council (IDCEC). EDRA44Providence ... 2013 at the Omni Providence Hotel in Providence, ...

(Date:5/20/2013)... 2013 Co-founder of Atlanta SEO ... keynote speaker at the 5th International INVEST Domaining & ... brings together company representatives and independent individuals from around ... marketing and investments. , The 2013 conference will take ... México from May 20 to 21. A networking city ...

(Date:5/20/2013)... The judge overseeing pretrial proceedings in the federal consolidation ... lawyers to be included in a plaintiffs’ leadership committee, ... the judge’s request, noting that its lawyers can ... Mirena side effects and how to file a lawsuit. ... some female lawyers to the committee. This followed requests ...

Breaking Medicine News(10 mins):Health News:Taking Actos for Two Years Caused Bladder Cancer, Alleges Lawsuit Filed by Parker Waichman LLP on Behalf of South Dakota Man 2 Health News:Tanning - FDA Wants Tanning Salons to Post Cancer Warning Signs 2 Health News:Environmental Design Research Conference to Feature AIA/CES, LA CES, and IDCEC Continuing Education Credits 2 Health News:EverSpark CEO to be Keynote Speaker at 5th International INVEST Domaining & Internet Marketing Conference in Mexico City 2 Health News:Mirena IUD Lawsuit Update: Judge Calls for More Input from Female Lawyers, Notes Rottenstein Law Group LLP 2

[0] Taking Actos for Two Years Caused Bladder Cancer, Alleges Lawsuit Filed by Parker Waichman LLP on Behalf of South Dakota Man [0] Tanning - FDA Wants Tanning Salons to Post Cancer Warning Signs [0] Environmental Design Research Conference to Feature AIA/CES, LA CES, and IDCEC Continuing Education Credits [0] EverSpark CEO to be Keynote Speaker at 5th International INVEST Domaining & Internet Marketing Conference in Mexico City [0] Mirena IUD Lawsuit Update: Judge Calls for More Input from Female Lawyers, Notes Rottenstein Law Group LLP

... someday help control anxiety, experts say, , , FRIDAY, May 15 ... anxiety isn,t something associated with heights, a job interview or ... state of worry and tension that affects twice as many ... slowly eroding their quality of life. , But a new ...

... ORLANDO A pill used for nerve pain offers women ... 45th Annual Meeting of the American Society of Clinical ... hot flash severity and frequency about 20 percent more than ... the same benefit as gabapentin, an older, related drug, as ...

... in GI and Endoscopy Nursing at SGNA 36th Annual ... Nurses and Associates, Inc. (SGNA) is proud to honor ... awards that recognize their dedication to the field and ... distinguished awards represent the best in GI and endoscopy ...

... Palatin Technologies, Inc. (NYSE Amex: PTN ) announced ... Palatin reported net income of $0.1 million, or $0.00 per basic ... to a net loss of $5.1 million, or $0.06 per basic ... revenues in the quarter ended March 31, 2009 were $5.2 million, ...

... 15 /PRNewswire-Asia-FirstCall/ -- Shengtai,Pharmaceutical, Inc. (OTC Bulletin Board: ... distributor of high-quality, pharmaceutical grade,glucose products in China, ... of fiscal 2009 ended March 31, 2009. , ... has impacted our operations thus far in,fiscal year ...

... Dr. Bruno E. Gerber is recognized in ... is a Consultant Orthopedic Surgeon with a special ... of the lower limbs. He also is employed ... development project regarding innovative orthopedic laser treatment.Dr. Gerber ...

Fear Response May Stem From Protein in Brain Mayo Clinic researchers say agent provides treatment option for women with hot flashes SGNA Honors Outstanding Gastroenterology and Endoscopy Professionals With Nationwide Awards Palatin Technologies, Inc. Reports Fiscal Year 2009 Third Quarter Results; Teleconference and Webcast to be held on May 15, 2009 Shengtai Pharmaceutical, Inc. Reports Unaudited Third Quarter Fiscal 2009 Financial Results Continental Who's Who Executive Press Release: Dr. Bruno E. Gerber - Medical Professional

... Blind Performance Specimens are intended for ... handling and transportation guidelines, including chain ... Testing Programs regulated by the Substance ... (SAMHSA), Health and Human Services Department ...

Lyphochek® Hemoglobin A1C Linearity Set is a human whole blood based product designed to verify linearity throughout the patient reportable range of hemoglobin A1C assays....

Liquichek Sedimentation Rate Control is a bilevel human whole blood based control designed to monitor both manual and automated methods for measuring erythrocyte sedimentation rates....

Liquichek Reticulocyte Control is a human whole blood based control designed to monitor manual and automated methods for counting reticulocytes. Assayed values are provided at three clinically signif...

Medicine Products:

Blind Performance Specimens Lyphochek Hemoglobin A1C Linearity Set Liquichek Sedimentation Rate Control Liquichek Reticulocyte Control